

Larry Gold, PhD

Chairman and Founder

A seasoned Chief Executive Officer with a strong portfolio of success leading the strategic development of technology innovation in the pharmaceutical, biotechnology, and life sciences industries. Instrumental in launching, developing, and significantly enhancing research products and services. Skilled at cultivating relationships with and presenting to investors, investment banks, analysts, and shareholders. Areas of expertise:

Strategic Planning
New Product Development
Strategic Alliances
Executive Presentations

Business Development
Opportunity Identification
Negotiations
Public Speaking

Mergers & Acquisitions
Investor & Shareholder Relations
Budget Administration
Capital Fundraising

Professional Experience

SomaLogic Inc

Founder, Chairman Emeritus, & former Chief Executive Officer **Boulder, CO** **1999 – Present**

SomaLogic is a biomarker discovery, development and diagnostics firm. Its proprietary technology is used to develop protein analysis tools for the life sciences community.

- Led all corporate strategic planning and business development, cultivated partnerships for joint ventures, collaborative marketing, investments, and academic collaborations.

NeXstar Pharmaceuticals

Founder, Chairman, Chief Scientific Officer **Boulder, CO** **1992 – 1999**

NeXstar Pharmaceuticals was a biotechnology company that discovered, developed, manufactured, and marketed proprietary pharmaceutical products to treat oncological, hematological, and infectious diseases.

- Negotiated and managed partnerships, strategic alliances, and collaborations.

Synergen

Founder, Director of Research **Boulder, CO** **1981 – 1992**

Synergen was a biotechnology company engaged in the discovery, development and manufacture of protein-based pharmaceuticals. The company's research was primarily concentrated in inflammation and neurobiology.

- Track record of researching, developing and commercializing products

Academic / Teaching Experience

University of Colorado

Opened CU – MCDB Laboratory 2006 – Present

University of Colorado

Serving as Professor and other academic support roles Dept. of Molecular, Cellular and Dev. Biology 1970 – Present

NeXstar Pharmaceuticals, Inc.

Chairman of the Board, Founder and Chief Scientific Officer 1991 – 1999

University of Colorado

Professor and Chairman, Department of Molecular, Cellular and Developmental Biology 1988 – 1993

University of Colorado

Professor, Department of Molecular, Cellular and Developmental Biology 1978 – 1988

University of Colorado

Associate Professor, Department of Molecular, Cellular and Developmental Biology 1974 – 1978

University of Colorado

Assistant Professor, Department of Molecular, Cellular and Developmental Biology 1969 – 1974

Geneva, Switzerland

Sabbatical Research with R.H. Epstein and A. Tissieres 1969 – 1970

Rockefeller University, New York, NY

NIH Postdoctoral Fellow under Dr. Fritz Lipmann 1967 – 1969

Education

Rockefeller University, New York, NY 1967 - 1969

Post-Doctoral Studies

University of Connecticut, Storrs, CT 1963 - 1967

Doctoral Studies

Yale University, New Haven, CT 1959 – 1963

Larry Gold, PhD

Annual Conference Host

Annual GoldLab Symposium	May 2010-present
14 th Annual GoldLab Symposium	May 2023
www.goldlabfoundation.org	

Awards and Fellowships

8th International Steven Hoogendijk Prize by the Dutch Batavian Society of Experimental Philosophy	2018
Pioneering Award (Colorado BioScience Association)	2013
Lifetime Achievement Award (Colorado BioScience Association)	2008
European Inventor of the Year Award (non-European Inventors)	2006
Frost & Sullivan Award for Technology Innovation	2004
CHIRON Corporation Biotechnology Research Award	1995

Board Positions

Colorado Longitudinal Study -- 13001 E. 17th Place, Building 500, Aurora, CO 80045
 CompleGen -- 1124 Columbia Street, Suite 662 - Seattle, WA 98104 / 206-447-9014
 GoldLab Foundation -- 347 UCB, Boulder, CO 80309 / 303-735-7112
 Plato BioPharma, Inc. -- 7581 W. 103rd Ave., Suite 300 Westminster, CO 80021 / 303-506-6960

Distinguished Memberships

Elected Member of the National Academy of Inventors	2017
Elected Member of the National Academy of Sciences	1995
Elected Member of the American Academy of Arts and Sciences	1993

Patents

Title	U.S. Patent	
	Number	Issue Date
Method for Purification and Identification of Sperm Cells	8,703,416	04/22/14
SELEX and PhotoSELEX	8,409,795	04/02/13
Method for Generating Aptamers with Improved Off-Rates	7,964,356	06/21/11
Methods and Reagents for Detecting Target Binding by Nucleic Acid Ligands	8,071,288	12/6/11
Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes	7,939,654	05/10/11
High Affinity Nucleic Acid Ligands of Complement System Proteins	7,964,572	06/21/11
Multiplexed Analyses of Test Samples	7,855,054	12/21/10
Method for Generating Aptamers with Improved Off-Rates	7,947,447	05/24/11
Method and Apparatus for the Automated Generation of Nucleic Acid Ligands	7,629,151	12/08/09
Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes	7,879,993	02/01/11
High Affinity Oligonucleotide Ligands to Vascular Endothelial Growth Factor (VEGF)	7,153,948	12/26/06
Nucleic Acid Ligand Diagnostic Biochip	7,709,192	05/04/10
High Affinity RNA Ligands of Basic Fibroblast Growth Factor	6,759,392	07/06/04
Determining Non-Nucleic Acid Molecule Binding To Target By Competition With Nucleic Acid Ligands	7,258,980	08/27/07
High Affinity Vascular Endothelial Growth Factor (VEGF) Receptor Nucleic Acid Ligands and Inhibitors	6,762,290	07/13/04

Larry Gold, PhD

Modified SELEX Processes Without Purified Protein	6,730,482	05/04/04
Methods of Producing Nucleic Acid Ligands	6,716,583	04/06/04
Method and Apparatus for the Automated Generation of Nucleic Acid Ligands	6,716,580	04/06/04
High Affinity TGF-Beta Nucleic Acid Ligands and Inhibitors	6,713,616	03/30/04
Conditional-SELEX	6,706,482	03/16/04
Methods and Compositions for Treatment of Tumors Using Nucleic Acid Ligands to Platelet-Derived Growth Factor	6,699,843	03/02/04
High Affinity Oligonucleotide Ligands to Vascular Endothelial Growth Factor (VEGF)	6,696,252	02/24/04
Bivalent Binding Molecules of 7 Transmembrane G Protein-Coupled Receptors	6,682,886	01/27/04
2'-Fluoropyrimidine Anti-Calf Intestinal Phosphatase Nucleic Acid Ligands	6,673,553	01/06/04
Aptamers as Reagents for High Throughput Screening	6,670,132	12/30/03
Systematic Evolution of Ligands by Exponential Enrichment: Tissue SELEX	6,613,526	09/02/03
Nucleotide-Based Prodrugs	6,610,841	08/26/03
Tenascin-C Nucleic Acid Ligands	6,596,491	07/22/03
Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes	6,582,918	06/24/03
Method for the automated generation of nucleic acid ligands	6,569,620	05/27/03
High Affinity Nucleic Acid Ligands of Complement System Proteins	6,566,343	05/20/03
High Affinity Nucleic Acid Ligands to Lectins	6,544,959	04/08/03
Nucleic acid ligand diagnostic biochip	6,544,776	04/08/03
Homogenous Detection of a Target Through Nucleic Acid Ligand-Ligand Beacon Interaction	6,531,286	03/11/03
Nucleoside Modifications by Palladium Catalyzed Methods	6,512,106	01/28/03
OB Receptor	6,506,887	01/14/03
Nucleic acid ligand diagnostic biochip	6,503,715	01/07/03
Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands	6,482,594	11/19/02
Systematic evolution of ligands by exponential enrichment: blended SELEX	6,465,189	10/15/02
Nucleic acid ligand complexes	6,465,188	10/15/02
Nucleic acid ligand diagnostic biochip	6,458,543	10/01/02
Photoselection of nucleic acid ligands	6,458,539	10/01/02
Urea Nucleosides as Therapeutic and Diagnostic Agents	6,441,161	08/27/02
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes	6,426,335	07/30/02
High affinity nucleic acid ligands of complement system proteins	6,395,888	05/28/02
2'-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands	6,387,635	05/14/02
Transcription-free SELEX	6,387,620	05/14/02
Systematic evolution of ligands by exponential enrichment: tissue SELEX	6,376,474	04/23/02
Modified SELEX processes without purified protein	6,376,190	04/23/02
Purine Nucleoside Modifications by Palladium Catalyzed Methods and Compounds Produced	6,355,787	03/12/02
High affinity TGF beta nucleic acid ligands and inhibitors	6,346,611	02/12/02
Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met	6,344,321	02/05/02
Methods of producing nucleic acid ligands	6,344,318	02/05/02
Nucleic Acid Ligands	6,331,398	12/18/01
Nucleic Acid Ligands to Integrins	6,331,394	12/18/01
Determining Non-Nucleic Acid Molecule Binding to Target by Competition with Nucleic Acid Ligand	6,329,145	12/11/01

Larry Gold, PhD

Systematic Evolution of Ligands by Exponential Enrichment: Chemi-SELEX	6,300,074	10/09/01
Systematic Evolution of Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solution SELEX	6,291,184	09/18/01
2'-Fluoropyrimidine Anti-Calf Intestinal Phosphatase Nucleic Acid Ligands	6,280,943	08/28/01
High Affinity Nucleic Acid Ligands to Lectins	6,280,932	08/28/01
Homogeneous Detection of a Target Through Nucleic Acid Ligand-Ligand Beacon Interaction	6,261,783	07/17/01
Truncation SELEX Method	6,261,774	07/17/01
Nucleic Acid Ligand Diagnostic Biochip	6,242,246	06/05/01
Tenascin-C Nucleic Acid Ligands	6,232,071	05/15/01
Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes	6,229,002	05/08/01
High Affinity Oligonucleotide Ligands to Growth Factors	6,207,816	03/27/01
High Affinity Nucleic Acid Ligands Containing Modified Nucleotides	6,184,364	02/06/01
Nucleic Acid Ligand Inhibitors to DNA Polymerases	6,183,967	02/06/01
High Affinity Ligands of Basic Fibroblast Growth Factor and Thrombin	6,177,557	01/23/01
Homogeneous Detection of a Target Through Nucleic Acid Ligand-Ligand Beacon Interaction	6,177,555	01/23/01
Nucleic Acid Ligands to CD40 Ligand	6,171,795	01/09/01
Vascular Endothelial Growth Factor (VEGF) nucleic Acid Ligand Complexes	6,168,778	01/02/01
Nucleic Acid Ligand Complexes	6,147,204	11/14/00
Urea Nucleosides as Therapeutic and Diagnostic Agents	6,143,882	11/07/00
High Affinity Nucleic Acid Ligands of Complement System Proteins	6,140,490	10/31/00
Nucleic Acid Ligands of Tissue Target	6,127,119	10/03/00
High Affinity TGF β Nucleic Acid Ligands and Inhibitors	6,124,449	09/26/00
Systematic Evolution of Ligands by Exponential Enrichment: Tissue SELEX	6,114,120	09/05/00
Nucleic Acid Ligands	6,110,900	08/29/00
Systematic Evolution of Ligands by Exponential Enrichment: Blended SELEX	6,083,696	07/04/00
Vascular Endothelial Growth Factor (VEGF) Nucleic Acid Ligand Complexes	6,051,698	04/18/00
High Affinity Nucleic Acid Ligands of Cytokines	6,028,186	02/22/00
Nucleoside Modifications by Palladium Catalyzed Methods	6,020,483	02/01/00
Nucleic Acid Ligand Inhibitors to DNA Polymerases	6,020,130	02/01/00
Systematic Evolution of Ligands by Exponential Enrichment: Tissue SELEX	6,013,443	01/11/00
Nucleic Acid Ligand Complexes	6,011,020	01/04/00
High Affinity Nucleic Acid Ligands to Lectins	6,001,988	12/14/99
System Evolution of Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solution SELEX	6,001,577	12/14/99
Systematic Evolution of Ligands by Exponential Enrichment: Chemi-SELEX	5,998,142	12/07/99
Homogeneous Detection of a Target Through Nucleic Acid Ligand-Ligand Beacon Interaction	5,989,823	11/23/99
High Affinity Nucleic Acid Ligands of Cytokines	5,972,599	10/26/99
Systematic Evolution of Ligands by Exponential Enrichment: Chemi-SELEX	5,962,219	10/05/99
Pyrimidine Nucleosides as Therapeutic and Diagnostic Agents	5,959,100	09/28/99
High Affinity Nucleic Acid Ligands Containing Modified Nucleotides	5,958,691	09/28/99
Nucleic Acid Ligand Inhibitors to DNA Polymerases	5,874,557	02/23/99

Larry Gold, PhD

Method for Detecting a Target Compound in a Substance using a Nucleic Acid Ligand	5,874,218	02/23/99
Method for the Production of Ligands Capable of Facilitating Chemical Reactions	5,871,924	02/16/99
High Affinity Nucleic Acid Ligands of CD4	5,869,641	02/09/99
Systematic Evolution of Ligands by Exponential Enrichment: Tissue SELEX	5,864,026	01/26/99
Flow Cell SELEX	5,861,254	01/19/99
Vascular Endothelial Growth Factor (VEGF) Nucleic Acid Ligand Complexes	5,859,228	01/12/99
Use of Nucleic Acid Ligands in Flow Cytometry	5,853,984	12/29/98
High Affinity Oligonucleotide Ligands to Chorionic Gonadotropin Hormone and Related Glycoprotein Hormones	5,849,890	12/15/98
High Affinity Oligonucleotide Ligands to Vascular Endothelial Growth Factor (VEGF)	5,849,479	12/15/98
High Affinity hKGF Nucleic Acid Ligands and Inhibitors	5,846,713	12/08/98
Method and Apparatus for Determining Consensus Secondary Structures for Nucleic Acid Sequences	5,843,732	12/01/98
Systematic Polypeptide Evolution By Reverse Translation (SPERT)	5,843,701	12/01/15
Method for Detecting a Target Molecule in a Sample Using a Nucleic Acid Ligand	5,843,653	12/01/98
Aptamer Analogs Specific for Biomolecules	5,840,867	11/24/98
High affinity hKGF Nucleic Acid Ligands and Inhibitors	5,837,834	11/17/98
High-Affinity Oligonucleotide Ligands to Chorionic Gonadotropin Hormone and Related Glycoprotein Hormones	5,837,456	11/17/98
Method of Producing Nucleic Acid Ligands	5,817,785	10/06/98
High Affinity Oligonucleotide Ligands to Vascular Endothelial Growth Factor (VEGF)	5,811,533	09/22/98
High Affinity Nucleic Acid Ligands of ICP4	5,795,721	08/18/98
Enzyme Linked Oligonucleotide Assays (ELONAS)	5,789,163	08/04/98
PARALLEL SELEX	5,789,160	08/04/98
Systematic Evolution of Ligands by Exponential Enrichment: Tissue SELEX	5,789,157	08/04/98
High Affinity ssDNA Ligands of HIV-1 Reverse Transcriptase	5,786,462	07/28/98
Purine Nucleoside Modifications by Palladium Catalyzed Methods	5,783,679	07/21/98
High Affinity Nucleic Acid Ligands to Lectins	5,780,228	07/14/98
Systematic Evolution of Ligands by Exponential Enrichment: Chimeric Selex	5,773,598	06/30/98
High Affinity Nucleic Acid Ligands to Lectins	5,766,853	06/16/98
Systematic Evolution of Ligands by Exponential Enrichment: Chemi-Selex	5,763,595	06/09/98
Systematic Evolution of Ligands by Exponential Enrichment: Tissue Selex	5,763,566	06/09/98
Systematic Evolution of Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solution Selex	5,763,177	06/09/98
Nucleic Acid Ligand Inhibitors to DNA Polymerases	5,763,173	06/09/98
Aptamers Specific for Biomolecules and Methods of Making	5,756,291	05/26/98
High Affinity HIV Integrase Inhibitors	5,756,287	05/26/98
Nucleic Acid Ligands of Tissue Target	5,750,342	05/12/98
Nucleic Acid Ligand Inhibitors of Human Neutrophil Elastase	5,734,034	03/31/98
High Affinity TGF β Nucleic Acid Ligands	5,731,424	03/28/98
High Affinity TGF β Nucleic Acid Ligands	5,731,144	03/28/98
High Affinity HIV-1 GAG Nucleic Acid Ligands	5,726,017	03/10/98
High Affinity PDGF Nucleic Acid Ligands	5,723,594	03/03/98
PARALLEL SELEX	5,723,592	03/03/98

Larry Gold, PhD

PARRELEL SELEX	5,723,289	03/03/98
Systematic Evolution of Ligands by Exponential Enrichment: Tissue SELEX	5,712,375	01/27/98
Method for Selecting Nucleic Acids on the Basis of Structure	5,707,796	01/13/98
Systematic Evolution of Ligands by Exponential Enrichment: Chemi-SELEX	5,705,337	01/06/98
Strategy for the Production of RNA from Immobilized Templates	5,700,667	12/23/97
Nucleic Acid Ligands (SELEX)	5,696,249	12/09/97
Nucleic Acid Ligand Inhibitors to DNA Polymerases	5,693,502	12/02/97
Nucleic Acid Ligands of Tissue Target	5,688,935	11/18/97
High-Affinity Oligonucleotide Ligands to Immunoglobulin E (IgE)	5,686,592	11/11/97
Systematic Evolution of Ligands by Exponential Enrichment: Blended SELEX	5,683,867	11/04/97
High Affinity PDGF Nucleic Acid Ligands	5,674,685	10/07/97
Nucleic Acid Ligands (SELEX)	5,670,637	09/23/97
High Affinity PDGF Nucleic Acid Ligands	5,668,264	09/16/97
High Affinity Nucleic Acid Ligands Containing Modified Nucleotides	5,660,985	08/26/97
High Affinity HIV Nucleocapsid Nucleic Acid Ligands	5,654,151	08/05/97
Target Detection Method Using Spectroscopically Detectable Nucleic Acid Ligands	5,650,275	07/22/97
High Affinity Oligonucleotide Ligands to the Tachykinin Substance P	5,648,214	07/15/97
Spectroscopically Detectable Nucleic Acid Ligands	5,641,629	06/24/97
High Affinity RNA Ligands of Basic Fibroblast Growth Factor	5,639,868	06/17/97
High Affinity Oligonucleotide Ligands to the Tachykinin Substance P	5,637,682	06/10/97
Ligands of HIV-1 TAT Protein	5,637,461	06/10/97
Systematic Evolution of Ligands by Exponential Enrichment: Chimeric SELEX	5,637,459	06/10/97
High Affinity HIV Nucleocapsid Nucleic Acid Ligands	5,635,615	06/03/97
Method for Palladium Catalyzed Carbon-Carbon Coupling and Products	5,633,361	05/27/97
High Affinity Oligonucleotide Ligands to Immunoglobulin E (IgE)	5,629,155	05/13/97
High Affinity Oligonucleotide Ligands to Secretory Phospholipase A2 (sPLA2)	5,622,828	04/22/97
Method of Producing Nucleic Acid Ligands	5,595,877	01/21/97
5-Modified Pyrimidines from Palladium Catalyzed Carbon-Carbon Coupling	5,591,843	01/07/97
High Affinity HIV Integrase Inhibitors	5,587,468	12/24/96
Method for identifying an Oligonucleotide Aptamer Specific for a Target	5,582,981	12/10/96
Purine Nucleoside Modifications by Palladium Catalyzed Methods	5,580,972	12/03/96
High Affinity Nucleic Acid Ligands that Discriminate Between Theophylline and Caffeine	5,580,737	12/03/96
Solution SELEX	5,567,588	10/22/96
Ligands of Thrombin	5,543,293	08/06/96
Ligands of HIV-1 tat Protein	5,527,894	06/18/96
Method for Identification of High Affinity DNA Ligands of HIV-1 Reverse Transcriptase	5,503,978	04/02/96
Nucleic Acid Ligands to HIV-RT and HIV-Rev	5,496,938	03/05/96
Ligands of Thrombin	5,476,766	12/19/95
Nucleic Acid Ligands	5,475,096	12/12/95
Nucleic Acid Ligand Inhibitors of Human Neutrophil Elastase	5,472,841	12/05/95
Ligands of bFGF	5,459,015	10/17/95

Larry Gold, PhD

Method for Palladium Catalyzed Carbon-Carbon Coupling and Products	5,428,149	06/27/95
Nucleic Acid Ligands	5,270,163	12/14/93